Element 3: Clinical Genome Sequencing at Scale

• Current NHGRI efforts:
  – eMERGE
  – CSER
  – UND
  – INSIGHT (NBS)
  – IGNITE
• What will landscape look like w/o NHGRI?
  – Where is coordinated action necessary?
  – When should market be relied upon?
• Partnership opportunities with other I/Cs
• ELSI integration
• What type of evidence is needed (e.g. RCTs? IED?)
• Duration of programs (e.g. CSER) and how to meet new challenges
• Zero-sum landscape/opportunity costs

Organizational structures to arrive at goals
(e.g. investigator initiated ↔ consortia)